The American Cancer Society now recommends routine prostate cancer screening with a PSA test, reversing its 2010 guidance, which made no universal recommendation. The new guidelines were released Thursday.

Men at average risk should get a PSA test every two years from age 50 to 69. Men at higher risk, due to race and family history, should start at 45. The ACS recommends yearly testing for all Black men starting at 45. Non-Black men should also test yearly from 45 if a close relative was diagnosed before age 65, or if more than one relative has had prostate cancer. If only one close relative was diagnosed at 65 or older, non-Black men should start at 45 but test every two years.

Men aged 70 to 74 should consult their doctor about continuing screening. The ACS does not recommend screening for men 75 and older.

The ACS says the update reflects new evidence since 2010 that screening saves lives. It also says advances in case management can reduce harms from overdiagnosis and overtreatment. The source notes that many men with prostate cancer will never have it grow or cause harm, while treatment can cause erectile dysfunction and urinary incontinence.

The guidance adds steps after a high PSA result. The ACS defines high as 3 ng/mL or higher for men under 70, and 6.5 ng/mL or higher for men 70 and older. Men should repeat the test first. If the result stays high, they should get a prostate MRI or a validated biomarker test. A biopsy is recommended only when cancer is highly suspected, such as with a very high PSA result. For men diagnosed with low-risk cancer, the ACS recommends active surveillance as the initial strategy.

Dr. Shanthi Sivendran, interim chief patient officer for the ACS, said in a statement: "By catching aggressive cancers with a simple PSA blood test, you open the door to highly effective treatments that protect your future. Meanwhile, lower-risk findings can be safely managed through careful, active surveillance."

The source reports that prostate cancer is one of the most common cancers in men and the second leading cause of cancer death in US men. The ACS estimates nearly 334,000 men will be diagnosed in 2026, and over 36,320 will die from the disease.

The source also notes that the US Preventive Services Task Force, a federal panel, is working on an update to its own prostate screening recommendation. It reports that the panel was recently overhauled by Health Secretary Robert F. Kennedy Jr., and that new members are reportedly rife with conflicts of interest.